What does “loss of exclusivity” mean for momelotinib in the US?
“Loss of exclusivity” generally refers to the point when a brand-name medicine no longer has patent and/or regulatory exclusivities that keep other manufacturers from filing an abbreviated approval application (like an ANDA for a generic) or from marketing a competing product without infringement risk. At that point, generic or biosimilar competition can enter the market sooner than if exclusivity were still in force.
When does momelotinib’s US exclusivity end?
I can’t answer the specific date from the information provided here. Determining the real “loss of exclusivity” timeline for momelotinib in the US requires the exact product name (brand), the listed patents and their expiry dates, and any FDA exclusivities shown in the Orange Book for that product.
How to check momelotinib’s exclusivity date yourself (US FDA Orange Book)
To find the actual US exclusivity/patent expiry information, look up the drug in the FDA’s Orange Book and review:
- Patent(s) listed for the product and their expiry dates
- Any “exclusivity” entries shown by FDA (these are separate from patents)
- Whether the relevant patents are already expired or expiring soon
This is the fastest way to pinpoint the date(s) when regulatory barriers drop and when generic entry becomes possible.
What could trigger generic entry after exclusivity is lost?
Even after exclusivity/patent expiry, market entry can still be affected by:
- Patent litigation: companies may still fight about infringement for related patents.
- Delayed regulatory approvals: an applicant may have filed but still be awaiting FDA action.
- Product-specific factors: dosing form, strengths, and labeling can influence timing.
Who makes momelotinib in the US, and what brand name should you search?
The exclusivity timeline depends on the exact FDA-listed product (brand name and dosage form). If you share the brand name (and strength/form), I can tell you exactly what to search for in the Orange Book and what to look for in the patent list.
If you mean “loss of exclusivity” for payers/coverage, not generics
Sometimes people use “loss of exclusivity” to mean when costs fall because:
- generics enter,
- insurers update formularies,
- and rebates reset.
That timing often follows—but doesn’t always exactly match—the legal/patent expiry dates.
---
Sources
I don’t have the required source material to cite the momelotinib exclusivity dates here. If you provide the brand name (US) or a link/screenshot to the FDA Orange Book listing you’re using, I can synthesize the exact “loss of exclusivity” timeline and what patents/exclusivities drive it.